Please try another search
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation. The Biologics Development Services segment offers end-to-end service offerings to biologics development and manufacturing for biopharma and biotech partners, as well as therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment constructs non-pathogenic microbial strains; and develops and produces industrial enzymes. The Cell Therapy segment discovers and develops chimeric antigen receptor CAR-T cell therapies for the treatment of liquid and solid tumors. It has a strategic partnership with Multiply Labs for automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Ye Wang | 55 | 2002 | Co-Founder, President & Executive Director |
Jiange Meng | 55 | 2010 | Executive Chairman |
Li Zhu | 73 | 2010 | Chief Strategy Officer & Executive Director |
Fangliang Zhang | 59 | 2022 | co-founder & Executive Director |
Luquan Wang | 55 | 2015 | Non-Executive Director |
Zumian Dai | 47 | 2015 | Independent Non-Executive Director |
Xuehai Wang | 49 | 2020 | Independent Non-Executive Director |
Jiuan Pan | 56 | 2018 | Independent Non-Executive Director |
George McDonald Church | 70 | 2019 | Member of Advisory Board |
Jiafen Wang | 73 | 2018 | Non-Executive Director |
Carl H. June | 70 | 2024 | Member of Advisory Board |
Chenyang Shi | 56 | 2024 | Independent Non-Executive Director |
Yiu Leung Cheung | 64 | 2024 | Independent Non-Executive Director |
David R. Liu | - | 2024 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review